Terms: = Germ cell tumor AND CALR, ENSG00000179218, 811, P27797, SSA, RO, FLJ26680, cC1qR AND Treatment
302 results:
1. Multidisciplinary surgical considerations for en bloc resection of sacral chordoma: review of recent advances and a contemporary single-center series.
Schroeder C; de Lomba WC; Leary OP; De la Garza Ramos R; Gillette JS; Miner TJ; Woo AS; Fridley JS; Gokaslan ZL; Zadnik Sullivan PL
Neurosurg Focus; 2024 May; 56(5):E7. PubMed ID: 38691863
[TBL] [Abstract] [Full Text] [Related]
2. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.
Giri S; Sahoo J
World J Gastroenterol; 2024 Mar; 30(12):1670-1675. PubMed ID: 38617746
[TBL] [Abstract] [Full Text] [Related]
3. IL-12-Overexpressed Nanoparticles Suppress the Proliferation of Melanoma Through Inducing ICD and Activating DC, CD8
Shen HH; Peng JF; Wang RR; Wang PY; Zhang JX; Sun HF; Liang Y; Li YM; Xue JN; Li YJ; Sun GB; Xie SY
Int J Nanomedicine; 2024; 19():2755-2772. PubMed ID: 38525008
[TBL] [Abstract] [Full Text] [Related]
4. The global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumours.
Clement DSVM; van Leerdam ME; Tesselaar MET; Cananea E; Martin W; Weickert MO; Sarker D; Ramage JK; Srirajaskanthan R
J Neuroendocrinol; 2024 Apr; 36(4):e13376. PubMed ID: 38389192
[TBL] [Abstract] [Full Text] [Related]
5. Personalized treatment of well-differentiated gastric neuroendocrine tumors based on clinicopathological classification and grading: A multicenter retrospective study.
Huang J; Liu H; Yang D; Xu T; Wang J; Li J
Chin Med J (Engl); 2024 Mar; 137(6):720-728. PubMed ID: 38384175
[TBL] [Abstract] [Full Text] [Related]
6. Incidence of Strabismus Post-Plaque Brachytherapy in Patients With Uveal Melanoma.
Huang JJ; Saleem A; Liao EX; Larocque M; Menon G; Murtha A; Solarte C; Weis E
Am J Ophthalmol; 2024 Jun; 262():161-169. PubMed ID: 38307213
[TBL] [Abstract] [Full Text] [Related]
7. treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.
Hinterleitner M; Pfeiffer R; Trautwein NF; Sipos B; Singer S; Nadalin S; Königsrainer A; Lauer UM; la Fougère C; Zender L; Hinterleitner C
Front Endocrinol (Lausanne); 2023; 14():1285529. PubMed ID: 38260136
[TBL] [Abstract] [Full Text] [Related]
8. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine tumor Patients.
Strosberg JR; Al-Toubah T; El-Haddad G; Reidy Lagunes D; Bodei L
J Nucl Med; 2024 Mar; 65(3):340-348. PubMed ID: 38238038
[TBL] [Abstract] [Full Text] [Related]
9. Real-world management practices and characteristics of patients with advanced melanoma initiated on immuno-oncology or targeted therapy in the first-line setting during the period 2015-2018 in Greece. The 'SUMMER' study: a retrospective multicenter chart review project.
Bafaloukos D; Kouzis P; Gouveris P; Boukovinas I; Kalbakis K; Baka S; Kyriakakis G; Moschou D; Molfeta A; Demiri S; Mavroudis D; Spanoudi F; Dimitriadis I; Gogas H
Melanoma Res; 2024 Apr; 34(2):152-165. PubMed ID: 38092014
[TBL] [Abstract] [Full Text] [Related]
10. Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients with metastatic gastroenteropancreatic neuroendocrine tumors.
Krishnan T; Safro M; Furlanetto DM; Gill S; Solar Vasconcelos JP; Stuart HC; Martineau P; Loree JM
J Neuroendocrinol; 2024 Jan; 36(1):e13360. PubMed ID: 38088132
[TBL] [Abstract] [Full Text] [Related]
11. Efficacy and tolerability of somatostatin analogues according to gender in patients with neuroendocrine tumors.
Ruggeri RM; Aini I; Gay S; Grossrubatscher EM; Mancini C; Tarsitano MG; Zamponi V; Isidori AM; Colao A; Faggiano A;
Rev Endocr Metab Disord; 2024 Apr; 25(2):383-398. PubMed ID: 38051470
[TBL] [Abstract] [Full Text] [Related]
12. Disparity in initiation of checkpoint inhibitors among commercially insured and Medicare Advantage patients with metastatic melanoma.
Li M; Liao K; Nowakowska M; Wehner M; Shih YT
J Manag Care Spec Pharm; 2023 Nov; 29(11):1232-1241. PubMed ID: 37889870
[No Abstract] [Full Text] [Related]
13. Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Honma Y; Ikeda M; Hijioka S; Matsumoto S; Ito T; Aoki T; Furuse J
Invest New Drugs; 2023 Dec; 41(6):777-786. PubMed ID: 37856005
[TBL] [Abstract] [Full Text] [Related]
14. Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy.
Hou C; Shi S; Gao M; Ji J; Ma C; Wang T; Chen T; Liu Y; Zhong J; Zheng Y; Ye J; Ke Y
J Neurooncol; 2023 Oct; 165(1):79-90. PubMed ID: 37819535
[TBL] [Abstract] [Full Text] [Related]
15. [Efficacy, prognosis and influencing factors of transcatheter arterial embolization in the treatment of neuroendocrine neoplasm liver metastases].
Zhang Y; Xu RT; Bai JA; Hu P; Li XY; Tian Y; Tang QY
Zhonghua Yi Xue Za Zhi; 2023 Oct; 103(37):2952-2958. PubMed ID: 37752055
[No Abstract] [Full Text] [Related]
16. Nomograms Based on MRI Radiomics for Differential Diagnosis and Predicting BRAFV600E Expression in Pleomorphic Xanthoastrocytoma and Ganglioglioma.
Kong X; Mao Y; Xi F; Li Y; Luo Y; Ma J
Acad Radiol; 2024 Mar; 31(3):1069-1081. PubMed ID: 37741731
[TBL] [Abstract] [Full Text] [Related]
17. Current role of Nuclear Medicine in the diagnosis and therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Georgakopoulos A
Hell J Nucl Med; 2023; 26 Suppl():49-51. PubMed ID: 37658564
[TBL] [Abstract] [Full Text] [Related]
18. Saikosaponin A mitigates the progression of Parkinson's disease via attenuating microglial neuroinflammation through TLR4/MyD88/NF-κB pathway.
Liu XL; Fan L; Yue BH; Lou Z
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(15):6956-6971. PubMed ID: 37606106
[TBL] [Abstract] [Full Text] [Related]
19. Enhancing information on stage at diagnosis for childhood cancer in Africa.
Liu B; Abraham N; Chitsike I; Sylvie CGL; Kambugu J; Stévy NMA; Pondy AHO; Renner L; Parkin DM
Pediatr Blood Cancer; 2023 Oct; 70(10):e30555. PubMed ID: 37432023
[TBL] [Abstract] [Full Text] [Related]
20. Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms.
Mosalem O; Sonbol MB; Halfdanarson TR; Starr JS
Best Pract Res Clin Endocrinol Metab; 2023 Sep; 37(5):101796. PubMed ID: 37414652
[TBL] [Abstract] [Full Text] [Related]
[Next]